Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Childhood Acute Myeloid Leukemia in Remission: full-pipeline trial registry
A small indexed set (8 trials) with no open enrollment listed right now.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · none currently recruiting · #2,176 of 28,707 conditions by registered trial count
Childhood Acute Myeloid Leukemia in Remission: 8 US clinical trials tracked, none currently recruiting.
Childhood Acute Myeloid Leukemia in Remission is the subject of 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 3 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Oncology Group, running 3 of these trials.
Enrollment posture brief
Registry condition childhood-acute-myeloid-leukemia-in-remission
OPEN 0 | RECR 0% | LATE 3 | EARLY 3 | RANK #2176 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Childhood Acute Myeloid Leukemia in Remission has no open enrollment in this registry pull (8 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Childhood Acute Myeloid Leukemia in Remission on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Childhood Acute Myeloid Leukemia in Remission is recruiting below its size-band peers.
0 of 8 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Childhood Acute Myeloid Leukemia in Remission research.
Children's Oncology Group accounts for 3 of 8 trials (37.5%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Childhood Acute Myeloid Leukemia in Remission trials plan to enrol fewer than 100 people.
Median target enrolment is 39 among the 8 trials that report a genuine target (sentinel values excluded). 6 of those (75%) plan for fewer than 100 participants.
-
Childhood Acute Myeloid Leukemia in Remission research is mostly interventional.
8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
8 total, page 1 of 1
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
Children's Oncology Group
NCT01305200
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Fred Hutchinson Cancer Center
NCT00027820
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
NCT00445744
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Children's Oncology Group
NCT00309907
Culturally Adapted Parenting Intervention for Spanish-Speaking Parents in Improving Outcomes of Younger Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Survivors at Risk for Late Neurocognitive Effects
City of Hope Medical Center
NCT02559557
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
Children's Oncology Group
NCT00450450
Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia
Fred Hutchinson Cancer Center
NCT00322101
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
Nohla Therapeutics
NCT01175785
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Childhood Acute Myeloid Leukemia in Remission records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Childhood Acute Myeloid Leukemia in Remission trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Childhood Acute Myeloid Leukemia in Remission page
8 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Childhood Acute Myeloid Leukemia in Remission trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Children's Oncology Group sponsors the most Childhood Acute Myeloid Leukemia in Remission trials on record, review their full trial history before evaluating a specific study. See Children's Oncology Group's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Childhood Acute Myeloid Leukemia in Remission condition card totals 8 registered trials; most-linked intervention cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.